FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Guus van Dongen

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Procedures

Concepts & Ideas

Tissue Distribution

Anatomy

Tumor Cell Line

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Ruth Cohen; Marijke Stigter-van Walsum; Gerard W M Visser; Danielle J Vugts; Guus A M S van Dongen
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.
Alex J Poot; Marissa Rongen; Robert Schuit; Marijke Stigter-van Walsum; Berend van der Wildt; Guus A M S van Dongen; Jonas Eriksson; N Harry Hendrikse; Albert D Windhorst
[(11)C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Derrek A Heuveling; Otto S Hoekstra; K Hakki Karagozoglu; C René Leemans; Guus A M S van Dongen; Annelies van Schie; Danielle J Vugts; Maqsood Yaqub; N Harry Hendrikse; Remco de Bree
Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Guus van Dongen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Ruth Cohen; Marijke Stigter-van Walsum; Gerard W M Visser; Danielle J Vugts; Guus A M S van Dongen
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.
Nature protocols 2013;8(5):1010-8.
2013: Alex J Poot; Marissa Rongen; Robert Schuit; Marijke Stigter-van Walsum; Berend van der Wildt; Guus A M S van Dongen; Jonas Eriksson; N Harry Hendrikse; Albert D Windhorst
[(11)C]Sorafenib: Radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Nuclear medicine and biology 2013;40(4):488-97.
2013: Derrek A Heuveling; Otto S Hoekstra; K Hakki Karagozoglu; C René Leemans; Guus A M S van Dongen; Annelies van Schie; Danielle J Vugts; Maqsood Yaqub; N Harry Hendrikse; Remco de Bree
Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013;54(4):585-9.
2013: Derrek A Heuveling; Otto S Hoekstra; Marc C Huisman; C René Leemans; Dario Neri; Remco de Bree; Leonardo Giovannoni; Danielle J Vugts; Guus A M S van Dongen
Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013;54(3):397-401.
2013: Danielle J Vugts; Gerard W M Visser; Guus A M S van Dongen
(89)Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals.
Current topics in medicinal chemistry 2013;13(4):446-57.
2012: Paul Slobbe; Alex J Poot; Albert D Windhorst; Guus A M S van Dongen
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
Drug discovery today 2012;17(21-22):1175-87.
2012: Peter R Luijten; Chrit T Moonen; Gert Storm; Guus A M S van Dongen; Daan J A Crommelin
Public-private partnerships in translational medicine: concepts and practical examples.
Journal of controlled release : official journal of the Controlled Release Society 2012;161(2):416-21.
2012: Derrek A Heuveling; C René Leemans; Wouter H Roos; Marian Baclayon; Johannes F de Boer; Remco de Bree; Mattijs de Groot; Gerard W M Visser; Gijs J L Wuite; Guus A M S van Dongen
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node.
European journal of nuclear medicine and molecular imaging 2012;39(7):1161-8.
2012: Guus A M S van Dongen; Alex J Poot; Danielle J Vugts
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(3):607-15.
2012: Maria J W D Vosjan; Jo Vercammen; Joost A Kolkman; Hilde Revets; Marijke Stigter-van Walsum; Guus A M S van Dongen
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
Molecular cancer therapeutics 2012;11(4):1017-25.
2012: Saiyada N F Rizvi; Guus A M S van Dongen; Arthur van Lingen; Otto J Visser; Maria J W D Vosjan; Josée M Zijlstra; Otto S Hoekstra; Peter C Huijgens; Mark Lubberink
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
European journal of nuclear medicine and molecular imaging 2012;39(3):512-20.
2012: Sabrina Oliveira; Rob C Roovers; Jord C Stam; Marijke Stigter-van Walsum; Paulus van Diest; Guus A M S van Dongen; Willem Mali; Paul M P van Bergen en Henegouwen
Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.
Molecular imaging 2012;11(1):33-46.
2011: Danielle J Vugts; Roland C M Vulders; Ron M Versteegen; Annelies Vervoort; Gerard W M Visser; J Koos D M Herscheid; Marc S Robillard; Marijke Stigter-van Walsum; Guus A M S van Dongen
Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.
Bioconjugate chemistry 2011;22(10):2072-81.
2011: Rob C Roovers; Guus A M S van Dongen; Arie J Verkleij; Maria J W D Vosjan; Renée C G de Bruin; Rachid el Khoulati; Kathryn M Ferguson; Toon Laeremans; Paul M P van Bergen en Henegouwen
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
International journal of cancer. Journal international du cancer 2011;129(8):2013-24.
2011: Derrek A Heuveling; Otto S Hoekstra; C René Leemans; Wouter H Roos; Marian Baclayon; Remco de Bree; Gerard W M Visser; Gijs J L Wuite; Guus A M S van Dongen
89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(10):1580-4.
2011: Ludwig J Dubois; Marco H M Janssen; Hartmuth C Kolb; Natasja G Lieuwes; Michel C Ollers; Wenny J M Peeters; Albert van der Kogel; Guus A M S van Dongen; Joseph C Walsh; Albert D Windhorst; Johan Bussink; Philippe Lambin
Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(35):14620-5.
2011: Regina Becker; Guus A M S van Dongen
EATRIS, a vision for translational research in Europe.
Journal of cardiovascular translational research 2011;4(3):231-7.
2011: Maria J W D Vosjan; Lars R Perk; Rob C Roovers; Gerard W M Visser; Marijke Stigter-van Walsum; Paul M P van Bergen en Henegouwen; Guus A M S van Dongen
Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.
European journal of nuclear medicine and molecular imaging 2011;38(4):753-63.
2011: Derrek A Heuveling; Remco de Bree; Guus A M S van Dongen
The potential role of non-FDG-PET in the management of head and neck cancer.
Oral oncology 2011;47(1):2-7.
2010: Guus A M S van Dongen; Maria J W D Vosjan
Immuno-positron emission tomography: shedding light on clinical antibody therapy.
Cancer biotherapy & radiopharmaceuticals 2010;25(4):375-85.
2010: Philippe Lambin; Steven F Petit; Hugo Aerts; Wouter J C van Elmpt; Cary J G Oberije; Maud H W Starmans; Ruud G P M van Stiphout; Guus A M S van Dongen; Kristoff Muylle; Patrick Flamen; André L A J Dekker; Dirk De Ruysscher
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010;96(2):145-52.
2010: Wouter B Nagengast; Maarten Alexander de Korte; Thijs H Oude Munnink; Hetty Timmer-Bosscha; Wilfred F A den Dunnen; Harry Hollema; Johan R de Jong; Michael Rugaard Jensen; Cornelia Quadt; Carlos Garcia-Echeverria; Guus A M S van Dongen; Marjolijn N Lub-de Hooge; Carolien P Schröder; Elisabeth G E de Vries
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(5):761-7.
2010: Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
Nature protocols 2010;5(4):739-43.
2010: Lars R Perk; Maria J W D Vosjan; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
European journal of nuclear medicine and molecular imaging 2010;37(2):250-9.
2009: Pontus K E Börjesson; Yvonne W S Jauw; Remco de Bree; Jan C Roos; Jonas A Castelijns; René Leemans; Guus A M S van Dongen; Ronald Boellaard
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(11):1828-36.
2009: Bernard M Tijink; Lars R Perk; Marianne Budde; Marijke Stigter-van Walsum; Gerard W M Visser; Reina W Kloet; Ludger M Dinkelborg; René Leemans; Dario Neri; Guus A M S van Dongen
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
European journal of nuclear medicine and molecular imaging 2009;36(8):1235-44.
2009: Eli C F Dijkers; Jos G W Kosterink; Anna P Rademaker; Lars R Perk; Guus A M S van Dongen; Joost Bart; Johan R de Jong; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(6):974-81.
2009: David Maussang; Ellen Langemeijer; Carlos P Fitzsimons; Marijke Stigter-van Walsum; Remco Dijkman; Martin K Borg; Erik Slinger; Andreas Schreiber; Detlef Michel; Cornelis P Tensen; Guus A M S van Dongen; Rob Leurs; Martine J Smit
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.
Cancer research 2009;69(7):2861-9.
2009: Hugo Aerts; Ludwig Dubois; Lars Perk; Peter Vermaelen; Guus A M S van Dongen; Bradly G Wouters; Philippe Lambin
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(1):123-31.
2008: Lars R Perk; Marijke Stigter-van Walsum; Gerard W M Visser; Reina W Kloet; Maria J W D Vosjan; René Leemans; Giuseppe Giaccone; Raffaella Albano; Paolo M Comoglio; Guus A M S van Dongen
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
European journal of nuclear medicine and molecular imaging 2008;35(10):1857-67.
2008: Bernard M Tijink; Toon Laeremans; Marianne Budde; Marijke Stigter-van Walsum; Torsten Dreier; Hans J de Haard; René Leemans; Guus A M S van Dongen
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
Molecular cancer therapeutics 2008;7(8):2288-97.
2007: Guus A M S van Dongen; Gerard W M Visser; Marjolijn N Lub-de Hooge; Elisabeth G de Vries; Lars R Perk
Immuno-PET: a navigator in monoclonal antibody development and applications.
The oncologist 2007;12(12):1379-89.
2007: Anna van Rhenen; Guus A M S van Dongen; Angèle Kelder; Elwin J Rombouts; Nicole Feller; Bijan Moshaver; Marijke Stigter-van Walsum; Sonja Zweegman; Gert Ossenkoppele; Gerrit Jan Schuurhuis
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
Blood 2007;110(7):2659-66.
2007: Rob C Roovers; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen
Nanobodies in therapeutic applications.
Current opinion in molecular therapeutics 2007;9(4):327-35.
2007: Wouter B Nagengast; Elisabeth G de Vries; Geke A P Hospers; Nanno H Mulder; Johan R de Jong; Harry Hollema; Adrienne H Brouwers; Guus A M S van Dongen; Lars R Perk; Marjolijn N Lub-de Hooge
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(8):1313-9.
2007: Ethaar El-Emir; Jason L J Dearling; Alexandra Huhalov; M P Robson; Geoffrey M Boxer; D Neri; Guus A M S van Dongen; E Trachsel; Richard H J Begent; R Barbara Pedley
Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
British journal of cancer 2007;96(12):1862-70.
2007: Marika Nestor; Tomas Ekberg; John Dring; Guus A M S van Dongen; Kenneth Wester; Vladimir Tolmachev; Matti Anniko
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(5):253-63.
2006: Lars R Perk; Otto J Visser; Marijke Stigter-van Walsum; Maria J W D Vosjan; Gerard W M Visser; Josée M Zijlstra; Peter C Huijgens; Guus A M S van Dongen
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
European journal of nuclear medicine and molecular imaging 2006;33(11):1337-45.
2006: Bernard M Tijink; Jan Buter; Remco de Bree; Giuseppe Giaccone; Margreet S Lang; Alexander Staab; René Leemans; Guus A M S van Dongen
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6064-72.
2006: Bernard M Tijink; Remco de Bree; Guus A M S van Dongen; René Leemans
How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients.
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2006;31(5):447-51.
2006: David Maussang; Dennis Verzijl; Marijke van Walsum; Rob Leurs; Jens Michael Holl; Olivier Pleskoff; Detlef Michel; Guus A M S van Dongen; Martine J Smit
Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(35):13068-73.
2006: Mark Lubberink; Annelies van Schie; Hugo W A M de Jong; Guus A M S van Dongen; Gerrit J J Teule
Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(8):1375-81.
2006: Bernard M Tijink; Dario Neri; René Leemans; Marianne Budde; Ludger M Dinkelborg; Marijke Stigter-van Walsum; Luciano Zardi; Guus A M S van Dongen
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(7):1127-35.
2006: Pontus K E Börjesson; Yvonne W S Jauw; Ronald Boellaard; Remco de Bree; Emile F I Comans; Jan C Roos; Jonas A Castelijns; Maria J W D Vosjan; J Alain Kummer; René Leemans; Adriaan A Lammertsma; Guus A M S van Dongen
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2133-40.
2006: Otto J Visser; Lars R Perk; Josée M Zijlstra; Guus A M S van Dongen; Peter C Huijgens; Arjan A van de Loosdrecht
Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2006;20(4):201-7.
2005: Lars R Perk; Gerard W M Visser; Maria J W D Vosjan; Marijke Stigter-van Walsum; Bernard M Tijink; René Leemans; Guus A M S van Dongen
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(11):1898-906.
2005: Marika Nestor; Mikael Persson; Guus A M S van Dongen; Holger J Jensen; Hans Lundqvist; Matti Anniko; Vladimir Tolmachev
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
European journal of nuclear medicine and molecular imaging 2005;32(11):1296-304.
2005: Otto J Visser; Josée M Zijlstra; Guus A M S van Dongen; Peter C Huijgens
[Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
Nederlands tijdschrift voor geneeskunde 2005;149(42):2324-8.
2005: Iris Verel; Gerard W M Visser; Guus A M S van Dongen
The promise of immuno-PET in radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46 Suppl 1():164S-71S.
2004: David R Colnot; Eline J C Nieuwenhuis; Dirk J Kuik; René Leemans; Janny Dijkstra; Gordon B Snow; Guus A M S van Dongen; Ruud H Brakenhoff
Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):7827-33.
2004: Iris Verel; Gerard W M Visser; Maria J W D Vosjan; Ronald Finn; Ronald Boellaard; Guus A M S van Dongen
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
European journal of nuclear medicine and molecular imaging 2004;31(12):1645-52.
2004: Pontus K E Börjesson; Ernst J Postema; Remco de Bree; Jan C Roos; René Leemans; Kalevi Kairemo; Guus A M S van Dongen
Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Oral oncology 2004;40(8):761-72.
2004: Adrienne H Brouwers; Iris Verel; Julliëtte E M van Eerd; Gerard Visser; Martijn Steffens; Egbert Oosterwijk; Frans H M Corstens; Wim J G Oyen; Guus A M S van Dongen; Otto Boerman
PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):155-63.
2004: Guus A M S van Dongen; Gerard W M Visser; Maarten B Vrouenraets
Photosensitizer-antibody conjugates for detection and therapy of cancer.
Advanced drug delivery reviews 2004;56(1):31-52.
2003: Ernst J Postema; Pontus K E Börjesson; Wilhelmina C A M Buijs; Jan C Roos; Henri Marres; Otto Boerman; Remco de Bree; Margreet Lang; Gerd Munzert; Guus A M S van Dongen; Wim J G Oyen
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(10):1690-9.
2003: Iris Verel; Gerard W M Visser; Ronald Boellaard; Otto Boerman; Julliëtte E M van Eerd; Gordon B Snow; Adriaan A Lammertsma; Guus A M S van Dongen
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(10):1663-70.
2003: Remco de Bree; Jan C Roos; Iris Verel; Guus A M S van Dongen; Gordon B Snow
Radioimmunodiagnosis of lymph node metastases in head and neck cancer.
Oral diseases 2003;9(5):241-8.
2003: David R Colnot; Jan C Roos; Remco de Bree; Abraham Wilhelm; J Alain Kummer; Gertraud Hanft; Karl-Heinz Heider; Gerd Stehle; Gordon B Snow; Guus A M S van Dongen
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Cancer immunology, immunotherapy : CII 2003;52(9):576-82.
2003: Ernst J Postema; John M M Raemaekers; Wim J G Oyen; Otto Boerman; C M P W Mandigers; David M Goldenberg; Guus A M S van Dongen; Frans H M Corstens
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3995S-4002S.
2003: Pontus K E Börjesson; Ernst J Postema; Jan C Roos; David R Colnot; Henri Marres; Mathijs H van Schie; Gerd Stehle; Remco de Bree; Gordon B Snow; Wim J G Oyen; Guus A M S van Dongen
Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3961S-72S.
2003: Iris Verel; Gerard W M Visser; Otto Boerman; Julliëtte E M van Eerd; Ron Finn; Ronald Boellaard; Maria J W D Vosjan; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Cancer biotherapy & radiopharmaceuticals 2003;18(4):655-61.
2003: Iris Verel; Gerard W M Visser; Ronald Boellaard; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(8):1271-81.
2003: Marika Nestor; Mikael Persson; Junping Cheng; Vladimir Tolmachev; Guus A M S van Dongen; Matti Anniko; Kalevi Kairemo
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
Bioconjugate chemistry 2003;14(4):805-10.
2003: Arnolda G de Nooij-van Dalen; Guus A M S van Dongen; Serge J Smeets; Eline J C Nieuwenhuis; Marijke Stigter-van Walsum; Gordon B Snow; Ruud H Brakenhoff
Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma.
International journal of cancer. Journal international du cancer 2003;103(6):768-74.
2003: Maarten B Vrouenraets; Gerard W M Visser; Gordon B Snow; Guus A M S van Dongen
Basic principles, applications in oncology and improved selectivity of photodynamic therapy.
Anticancer research 2003;23(1B):505-22.
2002: David R Colnot; Gert Ossenkoppele; Jan C Roos; Jasper J Quak; Remco de Bree; Pontus K E Börjesson; Peter C Huijgens; Gordon B Snow; Guus A M S van Dongen
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3401-6.
2002: Iris Verel; Karl-Heinz Heider; Miranda Siegmund; Elínborg Ostermann; Erik Patzelt; Marlies Sproll; Gordon B Snow; Günther R Adolf; Guus A M S van Dongen
Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
International journal of cancer. Journal international du cancer 2002;99(3):396-402.
2002: Maarten B Vrouenraets; Gerard W M Visser; Marÿke Stigter; Hugo Oppelaar; Gordon B Snow; Guus A M S van Dongen
Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro.
International journal of cancer. Journal international du cancer 2002;98(5):793-8.
2001: Albert A Geldof; Johan C van Mourik; Martin A Rooimans; Fré Arwert; Mario A J A Hermsen; Inge L Schadee-Eestermans; Guus A M S van Dongen; P van der Valk; Paul Lips; Gerrit J J Teule
Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609).
Thyroid : official journal of the American Thyroid Association 2001;11(10):909-17.
2001: David R Colnot; Abraham Wilhelm; Jacqueline Cloos; Jan C Roos; Remco de Bree; Jasper J Quak; Gordon B Snow; Guus A M S van Dongen
Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(9):1364-7.
2001: David R Colnot; Jasper J Quak; Jan C Roos; Remco de Bree; Abraham Wilhelm; Gordon B Snow; Guus A M S van Dongen
Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
Head & neck 2001;23(7):559-65.
2001: Gerard W M Visser; Rob P Klok; J W Gebbinck; T ter Linden; Guus A M S van Dongen; Carla F M Molthoff
Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(3):509-19.
2001: Maarten B Vrouenraets; Gerard W M Visser; Marÿke Stigter; Hugo Oppelaar; Gordon B Snow; Guus A M S van Dongen
Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy.
Cancer research 2001;61(5):1970-5.
2000: David R Colnot; Jasper J Quak; Jan C Roos; Arthur van Lingen; Abraham Wilhelm; G J van Kamp; Peter C Huijgens; Gordon B Snow; Guus A M S van Dongen
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(12):1999-2010.
2000: Maarten B Vrouenraets; Gerard W M Visser; C Loup; Bernard MEUNIER; Marÿke Stigter; Hugo Oppelaar; Fiona A Stewart; Gordon B Snow; Guus A M S van Dongen
Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.
International journal of cancer. Journal international du cancer 2000;88(1):108-14.
2000: J W Stroomer; Jan C Roos; M Sproll; Jasper J Quak; Karl-Heinz Heider; B J Wilhelm; Jonas A Castelijns; R Meyer; M O Kwakkelstein; Gordon B Snow; Günther R Adolf; Guus A M S van Dongen
Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3046-55.
1999: NL Van Hal; Guus A M S van Dongen; CB Ten Brink; Karl-Heinz Heider; I Rech-Weichselbraun; Gordon B Snow; Ruud H Brakenhoff
Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3534-41.
1999: NL Van Hal; Guus A M S van Dongen; Marijke Stigter-van Walsum; Gordon B Snow; Ruud H Brakenhoff
Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma.
International journal of cancer. Journal international du cancer 1999;82(6):837-45.
1999: Ruud H Brakenhoff; J G Stroomer; CB Ten Brink; Remco de Bree; S M Weima; Gordon B Snow; Guus A M S van Dongen
Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):725-32.
1999: Maarten B Vrouenraets; Gerard W M Visser; Fiona A Stewart; Marÿke Stigter; Hugo Oppelaar; P E Postmus; Gordon B Snow; Guus A M S van Dongen
Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy.
Cancer research 1999;59(7):1505-13.
1998: Remco de Bree; Dirk J Kuik; Jasper J Quak; Jan C Roos; Michiel van den Brekel; Jonas A Castelijns; F W van Wagtendonk; Henri N J M Greuter; Gordon B Snow; Guus A M S van Dongen
The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients.
European journal of nuclear medicine 1998;25(11):1562-5.
1998: FB van Gog; Gerard W M Visser; R W Gowrising; Gordon B Snow; Guus A M S van Dongen
Synthesis and evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting strategies.
Nuclear medicine and biology 1998;25(7):611-9.
1998: FB van Gog; Ruud H Brakenhoff; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
International journal of cancer. Journal international du cancer 1998;77(1):13-8.
1998: E Kievit; FB van Gog; Hennie M M Schlüper; Guus A M S van Dongen; HERBERT PINEDO; Epie Boven
[186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of the efficacy in experimental human ovarian cancer.
Nuclear medicine and biology 1998;25(1):37-45.
1997: FB van Gog; Gerard W M Visser; J W Stroomer; Jan C Roos; Gordon B Snow; Guus A M S van Dongen
High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
Cancer 1997;80(12 Suppl):2360-70.
1997: NL Van Hal; Guus A M S van Dongen; CB Ten Brink; J N Herron; Gordon B Snow; Ruud H Brakenhoff
Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope.
Cancer immunology, immunotherapy : CII 1997;45(2):88-92.
1997: E Kievit; FB van Gog; Hennie M M Schlüper; Guus A M S van Dongen; HERBERT PINEDO; Epie Boven
Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
International journal of radiation oncology, biology, physics 1997;38(4):813-23.
1997: FB van Gog; Ruud H Brakenhoff; Gordon B Snow; Guus A M S van Dongen
Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.
Cancer immunology, immunotherapy : CII 1997;44(2):103-11.
1997: Remco de Bree; Jan C Roos; Marian A B D Plaizier; Jasper J Quak; G J van Kamp; W den Hollander; Gordon B Snow; Guus A M S van Dongen
Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
British journal of cancer 1997;75(7):1049-60.
1996: N L Van Hal; Guus A M S van Dongen; E M Rood-Knippels; Paul Van Der Valk; Gordon B Snow; Ruud H Brakenhoff
Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform.
International journal of cancer. Journal international du cancer 1996;68(4):520-7.
1996: Guus A M S van Dongen; R M Brakenhoff; C T ten Brink; FB van Gog; Remco de Bree; Jasper J Quak; Gordon B Snow
Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.
Anticancer research 1996;16(4C):2409-13.
1996: FB van Gog; Gerard W M Visser; Rob P Klok; R van der Schors; Gordon B Snow; Guus A M S van Dongen
Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(2):352-62.
1995: Remco de Bree; Jan C Roos; Jasper J Quak; W den Hollander; Gordon B Snow; Guus A M S van Dongen
Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(6):591-8.
1995: Ruud H Brakenhoff; FB van Gog; J E Looney; M van Walsum; Gordon B Snow; Guus A M S van Dongen
Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.
Cancer immunology, immunotherapy : CII 1995;40(3):191-200.
1994: Remco de Bree; Jan C Roos; Jasper J Quak; W den Hollander; Gordon B Snow; Guus A M S van Dongen
Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract.
Nuclear medicine communications 1994;15(8):613-27.
1994: F M Gripp; Jasper J Quak; H Leverstein; A Schrijvers; M Gerretsen; Ruud H Brakenhoff; Guus A M S van Dongen; Gordon B Snow; A Rapoport
Monoclonal antibodies for diagnosis and therapy of squamous cell carcinoma of the head and neck.
São Paulo medical journal = Revista paulista de medicina 1994;112(3):612-21.
1994: Remco de Bree; Jan C Roos; Jasper J Quak; W den Hollander; Michiel van den Brekel; J E van der Wal; H Tobi; Gordon B Snow; Guus A M S van Dongen
Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 IgG or F(ab')2.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(5):775-83.
1994: Jasper J Quak; Guus A M S van Dongen
Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 1994;251(1):1-5.
1994: M Gerretsen; Jasper J Quak; Ruud H Brakenhoff; Gordon B Snow; Guus A M S van Dongen
The feasibility of radioimmunotherapy of head and neck cancer.
European journal of cancer. Part B, Oral oncology 1994;30B(2):82-7.
1994: M Gerretsen; Gerard W M Visser; Ruud H Brakenhoff; M van Walsum; Gordon B Snow; Guus A M S van Dongen
Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.
Cell biophysics 1994;24-25():135-42.
1993: Gerard W M Visser; M Gerretsen; J D M Herscheid; Gordon B Snow; Guus A M S van Dongen
Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(11):1953-63.
1993: Jasper J Quak; M Gerretsen; R De Bree; R Brakenhof; Guus A M S van Dongen; Gordon B Snow
Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours.
Anticancer research 1993;13(6B):2533-9.
1993: A H Schrijvers; Jasper J Quak; A M Uyterlinde; M van Walsum; Chris J L M Meijer; Gordon B Snow; Guus A M S van Dongen
MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
Cancer research 1993;53(18):4383-90.
1993: M Gerretsen; Gerard W M Visser; M van Walsum; Chris J L M Meijer; Gordon B Snow; Guus A M S van Dongen
186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Cancer research 1993;53(15):3524-9.
1993: MP Copper; Boudewijn J M Braakhuis; N de Vries; Guus A M S van Dongen; J J Nauta; Gordon B Snow
A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials.
Cancer 1993;71(3):825-30.
1992: M Gerretsen; A H Schrijvers; M van Walsum; Boudewijn J M Braakhuis; Jasper J Quak; Chris J L M Meijer; Gordon B Snow; Guus A M S van Dongen
Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
British journal of cancer 1992;66(3):496-502.
1992: Guus A M S van Dongen; H Leverstein; Jan C Roos; Jasper J Quak; Michiel van den Brekel; Arthur van Lingen; H J Martens; J A Castelijns; Gerard W M Visser; Chris J L M Meijer
Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal antibody E48 F(ab')2.
Cancer research 1992;52(9):2569-74.
1992: Jasper J Quak; H G Schrijvers; J G Brakkee; H D Davis; Rik J Scheper; Chris J L M Meijer; Gordon B Snow; Guus A M S van Dongen
Expression and characterization of two differentiation antigens in human stratified squamous epithelia and carcinomas.
International journal of cancer. Journal international du cancer 1992;50(4):507-13.
1992: A H Schrijvers; M Gerretsen; M van Walsum; Boudewijn J M Braakhuis; Jasper J Quak; Gordon B Snow; Guus A M S van Dongen
Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.
Cancer immunology, immunotherapy : CII 1992;34(4):252-8.
1991: Jasper J Quak; M Gerretsen; A H Schrijvers; Chris J L M Meijer; Guus A M S van Dongen; Gordon B Snow
Detection of squamous cell carcinoma xenografts in nude mice by radiolabeled monoclonal antibody E48.
Archives of otolaryngology--head & neck surgery 1991;117(11):1287-91.
1991: A H Schrijvers; M Gerretsen; J M Fritz; M van Walsum; Jasper J Quak; Gordon B Snow; Guus A M S van Dongen
Evidence for a role of the monoclonal antibody E48 defined antigen in cell-cell adhesion in squamous epithelia and head and neck squamous cell carcinoma.
Experimental cell research 1991;196(2):264-9.
1991: M Gerretsen; Jasper J Quak; J S Suh; M van Walsum; Chris J L M Meijer; Gordon B Snow; Guus A M S van Dongen
Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
British journal of cancer 1991;63(1):37-44.
1991: Boudewijn J M Braakhuis; Guus A M S van Dongen; J B Vermorken; Gordon B Snow
Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.
Cancer research 1991;51(1):211-4.
1990: Jasper J Quak; Guus A M S van Dongen; J G Brakkee; D J Hayashida; A J Balm; Gordon B Snow; Chris J L M Meijer
Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen.
Hybridoma 1990;9(4):377-87.
1990: Jasper J Quak; Guus A M S van Dongen; M A Koken; J G Brakkee; Rik J Scheper; A J Balm; L de Jong; Gordon B Snow; Chris J L M Meijer
Identification of a 43-kDa nuclear antigen associated with proliferation by monoclonal antibody K 112.
International journal of cancer. Journal international du cancer 1990;46(1):50-5.
1990: Boudewijn J M Braakhuis; Guus A M S van Dongen; Godefridus J Peters; M van Walsum; Gordon B Snow
Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Cancer letters 1990;49(2):133-7.
1990: Jasper J Quak; A J Balm; Guus A M S van Dongen; J G Brakkee; Rik J Scheper; Gordon B Snow; Chris J L M Meijer
A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia.
The American journal of pathology 1990;136(1):191-7.
1989: D H Brown; Boudewijn J M Braakhuis; Guus A M S van Dongen; M van Walsum; M Bagnay; Gordon B Snow
Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
Anticancer research 1989;9(6):1549-52.
1989: B J Braakhuis; Guus A M S van Dongen; M Bagnay; M van Walsum; Gordon B Snow
Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice.
Head & neck 1989;11(6):511-5.
1989: Boudewijn J M Braakhuis; D A Laarman; J J Nauta; M van Walsum; Guus A M S van Dongen; Gordon B Snow
Transplantability of human head and neck squamous cell carcinomas in athymic nude mice.
Archives of otolaryngology--head & neck surgery 1989;115(9):1076-8.
1989: Guus A M S van Dongen; Boudewijn J M Braakhuis; A Leyva; HR Hendriks; B B Kipp; M Bagnay; Gordon B Snow
Anti-tumor and differentiation-inducing activity of N,N-dimethylformamide (DMF) in head-and-neck cancer xenografts.
International journal of cancer. Journal international du cancer 1989;43(2):285-92.
1988: Boudewijn J M Braakhuis; Guus A M S van Dongen; M van Walsum; A Leyva; Gordon B Snow
Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].
Investigational new drugs 1988;6(4):299-304.
1988: Guus A M S van Dongen; Boudewijn J M Braakhuis; M Bagnay; A Leyva; Gordon B Snow
Activity of differentiation-inducing agents and conventional drugs in head and neck cancer xenografts.
Acta oto-laryngologica 1988;105(5-6):488-93.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.